Gauri G Rao

List of Publications by Year
in descending order

52 papers	1,017 citations	471509 17 h-index	477307 29 g-index
52 all docs	52 docs citations	52 times ranked	1290 citing authors

#	Article	IF	Citations
1	A systematic review and meta-analysis of treatment outcomes following antibiotic therapy among patients with carbapenem-resistant Klebsiella pneumoniae infections. International Journal of Antimicrobial Agents, 2020, 55, 105833.	2.5	81
2	Personalizing Polymyxin B Dosing Using an Adaptive Feedback Control Algorithm. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	67
3	Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance. Journal of Antimicrobial Chemotherapy, 2015, 70, 1434-1442.	3.0	60
4	Therapeutic Drug Monitoring Can Improve Linezolid Dosing Regimens in Current Clinical Practice: A Review of Linezolid Pharmacokinetics and Pharmacodynamics. Therapeutic Drug Monitoring, 2020, 42, 83-92.	2.0	59
5	Precision Dosing: Public Health Need, Proposed Framework, and Anticipated Impact. Clinical and Translational Science, 2017, 10, 443-454.	3.1	55
6	Polymyxin B in combination with meropenem against carbapenemase-producing Klebsiella pneumoniae: pharmacodynamics and morphological changes. International Journal of Antimicrobial Agents, 2017, 49, 224-232.	2.5	46
7	Paradoxical Effect of Polymyxin B: High Drug Exposure Amplifies Resistance in Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy, 2016, 60, 3913-3920.	3.2	43
8	Clinical challenges treatingStenotrophomonas maltophiliainfections: an update. JAC-Antimicrobial Resistance, 2022, 4, dlac040.	2.1	39
9	Development of a Minimal Physiologically-Based Pharmacokinetic Model to Simulate Lung Exposure in Humans Following Oral Administration of Ivermectin for COVID-19 Drug Repurposing. Journal of Pharmaceutical Sciences, 2020, 109, 3574-3578.	3.3	37
10	Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii : pharmacodynamics of new dosing strategies. Journal of Antimicrobial Chemotherapy, 2016, 71, 3148-3156.	3.0	36
11	New Dosing Strategies for an Old Antibiotic: Pharmacodynamics of Front-Loaded Regimens of Colistin at Simulated Pharmacokinetics in Patients with Kidney or Liver Disease. Antimicrobial Agents and Chemotherapy, 2014, 58, 1381-1388.	3.2	30
12	Triple combination antibiotic therapy for carbapenemase-producing Klebsiella pneumoniae: a systematic review. Annals of Clinical Microbiology and Antimicrobials, 2017, 16, 76.	3.8	30
13	Combinatorial pharmacodynamics of polymyxin B and tigecycline against heteroresistant Acinetobacter baumannii. International Journal of Antimicrobial Agents, 2016, 48, 331-336.	2.5	28
14	Polymyxin B in Combination with Rifampin and Meropenem against Polymyxin B-Resistant KPC-Producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	27
15	Combination treatment with extended-infusion ceftazidime/avibactam for a KPC-3-producing Klebsiella pneumoniae bacteraemia in a kidney and pancreas transplant patient. International Journal of Antimicrobial Agents, 2016, 48, 225-227.	2.5	22
16	A mechanismâ€based pharmacokinetic model of remdesivir leveraging interspecies scaling to simulate COVIDâ€19 treatment in humans. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 89-99.	2.5	21
17	Optimization of Polymyxin B in Combination with Doripenem To Combat Mutator Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2016, 60, 2870-2880.	3.2	18
18	Evaluation of Activity and Emergence of Resistance of Polymyxin B and ZTI-01 (Fosfomycin for) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 67 62, .	3.2	18

#	Article	IF	Citations
19	Synergistic Combination of Polymyxin B and Enrofloxacin Induced Metabolic Perturbations in Extensive Drug-Resistant Pseudomonas aeruginosa. Frontiers in Pharmacology, 2019, 10, 1146.	3.5	17
20	Antibiotic pharmacokinetic/pharmacodynamic modelling: MIC, pharmacodynamic indices and beyond. International Journal of Antimicrobial Agents, 2021, 58, 106368.	2.5	17
21	Mechanismâ€Based Disease Progression Model Describing Hostâ€Pathogen Interactions During the Pathogenesis of Acinetobacter baumannii Pneumonia. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 507-516.	2.5	16
22	Novel Polymyxin Combination with the Antiretroviral Zidovudine Exerts Synergistic Killing against NDM-Producing Multidrug-Resistant Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	16
23	Critical Need for Clarity in Polymyxin B Dosing. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	15
24	Polymyxin B in Combination with Enrofloxacin Exerts Synergistic Killing against Extensively Drug-Resistant Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	15
25	Assessing the predictive performance of population pharmacokinetic models for intravenous polymyxin B in critically ill patients. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 1525-1537.	2.5	15
26	The development and validation of a simple liquid chromatographyâ€“tandem mass spectrometry method for polymyxin B1 and B2 quantification in different matrices. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1065-1066, 112-118.	2.3	13
27	Moving From Pointâ€Based Analysis to Systemsâ€Based Modeling: Integration of Knowledge to Address Antimicrobial Resistance Against MDR Bacteria. Clinical Pharmacology and Therapeutics, 2021, 110, 1196-1206.	4.7	13
28	Pharmacodynamic Variability beyond That Explained by MICs. Antimicrobial Agents and Chemotherapy, 2013, 57, 1730-1735.	3.2	12
29	In Vitro Assessment of Combined Polymyxin B and Minocycline Therapy against Klebsiella pneumoniae Carbapenemase (KPC)-Producing K. pneumoniae. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	12
30	Comparative metabolomics revealed key pathways associated with the synergistic killing of multidrug-resistant Klebsiella pneumoniae by a bacteriophage-polymyxin combination. Computational and Structural Biotechnology Journal, 2022, 20, 485-495.	4.1	12
31	Polymyxins for the treatment of lower respiratory tract infections: lessons learned from the integration of clinical pharmacokinetic studies and clinical outcomes. International Journal of Antimicrobial Agents, 2021, 57, 106328.	2.5	11
32	Impact of Antibiotic Resistance on Treatment of Pneumococcal Disease in Ethiopia: An Agent-Based Modeling Simulation. American Journal of Tropical Medicine and Hygiene, 2019, 101, 1042-1053.	1.4	11
33	Mechanisms Underlying Synergistic Killing of Polymyxin B in Combination with Cannabidiol against Acinetobacter baumannii: A Metabolomic Study. Pharmaceutics, 2022, 14, 786.	4.5	11
34	Evaluation Strategies for Tripleâ€Drug Combinations against Carbapenemaseâ€Producing Klebsiella Pneumoniae in an In Vitro Hollowâ€Fiber Infection Model. Clinical Pharmacology and Therapeutics, 2021, 109, 1074-1080.	4.7	10
35	Unique mechanistic insights into pathways associated with the synergistic activity of polymyxin B and caspofungin against multidrug-resistant Klebsiella pneumoniae. Computational and Structural Biotechnology Journal, 2022, 20, 1077-1087.	4.1	10
36	Oseltamivir Population Pharmacokinetics in the Ferret: Model Application for Pharmacokinetic/Pharmacodynamic Study Design. PLoS ONE, 2015, 10, e0138069.	2.5	8

#	Article	IF	Citations
37	Treatment of infections caused by Gram-negative pathogens: current status on the pharmacokinetics/pharmacodynamics of parenteral and inhaled polymyxins in patients. International Journal of Antimicrobial Agents, 2020, 56, 106199.	2.5	8
38	Reapproaching Old Treatments: Considerations for PK/PD Studies on Phage Therapy for Bacterial Respiratory Infections. Clinical Pharmacology and Therapeutics, 2021, 109, 1443-1456.	4.7	7
39	Validation of a Model Predicting Anti-infective Lung Penetration in the Epithelial Lining Fluid of Humans. Pharmaceutical Research, 2018, 35, 26.	3.5	6
40	Insights Into Patient Variability During Ivacaftor-Lumacaftor Therapy in Cystic Fibrosis. Frontiers in Pharmacology, 2021, 12, 577263.	3.5	6
41	Value of pneumococcal vaccination in controlling the development of antimicrobial resistance (AMR): Case study using DREAMR in Ethiopia. Vaccine, 2021, 39, 6700-6711.	3.8	6
42	Relative Bioavailability of Orally Administered Fosphenytoin Sodium Injection Compared with Phenytoin Sodium Injection in Healthy Volunteers. Pharmacotherapy, 2015, 35, 482-488.	2.6	5
43	Multi-scale model of drug induced adaptive resistance of Gram-negative bacteria to polymyxin B. PLoS ONE, 2017, 12, e0171834.	2.5	5
44	Comparison of the composition and in vitro activity of polymyxin B products. International Journal of Antimicrobial Agents, 2018, 52, 365-371.	2.5	5
45	Pharmacodynamic and immunomodulatory effects of polymyxin B in combination with fosfomycin against KPC-2-producing Klebsiella pneumoniae. International Journal of Antimicrobial Agents, 2022, 59, 106566.	2.5	4
46	Knowledge dissemination and central indexing of resources in pharmacometrics: an ISOP education working group initiative. Journal of Pharmacokinetics and Pharmacodynamics, 2022, 49, 397-400.	1.8	3
47	Definition and Validation of a Novel Metric of Erythropoiesisâ€Stimulating Agent Response in Hemodialysis Patients. Journal of Clinical Pharmacology, 2019, 59, 418-426.	2.0	2
48	Mortality, clinical and microbiological response following antibiotic therapy among patients with carbapenem-resistant Klebsiella pneumoniae infections (a meta-analysis dataset). Data in Brief, 2020, 28, 104907.	1.0	2
49	The Complex Roadmap to Infectious Disease Innovation: The Intersection of Bugs, Drugs, and Special Populations. Clinical Pharmacology and Therapeutics, 2021, 109, 793-796.	4.7	2
50	Insights and lessons learned from a prospective clinical pharmacology study in allogeneic hematopoietic stem cell transplant during the COVIDâ€19 pandemic. Clinical and Translational Science, 2022, 15, 583-587.	3.1	2
51	Intraventricular Drug Delivery and Sampling for Pharmacokinetics and Pharmacodynamics Study. Journal of Visualized Experiments, 2022, , .	0.3	2
52	Effect of polymyxin B-containing regimens on renal function for the treatment of carbapenem-resistant Enterobacteriacea mediastinitis. Brazilian Journal of Infectious Diseases, 2018, 22, 51-54.	0.6	1